Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLC

Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLC provides an overview of key clinical data on immunotherapy in lung cancers, with many studies defining new standards of care over the past year. Our distinguished Chair, Dr. Benjamin Levy, along with our expert faculty panel, will discuss how you can apply biomarker data for treatment selection, and how to manage immune-related adverse events in your patients with lung cancer. From stage III disease to metastatic non–small cell lung cancer (NSCLC) as well as small cell lung cancer (SCLC), this activity will help you provide state-of-the-art management for your patients.

Benefits of Participating

  • Learn about newly defined standards of care with immunotherapy in patients with lung cancer
  • Find out how experts choose between different immunotherapy-based regimens
  • Gain insights into multidisciplinary management of treatment-related adverse events associated with immunotherapy

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, pulmonologists, nurse practitioners, physician assistants, and nurses who treat and manage patients with lung cancer. Other healthcare professionals interested in the treatment and management of patients with lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Describe the rationale underlying the use of immune checkpoint inhibition–based strategies for the management of NSCLC
  • Assess clinical trial designs and evidence on immune checkpoint inhibition, including future application to evolving treatment paradigms for patients with locally advanced, unresectable and metastatic forms of NSCLC
  • Discuss evolving uses for biomarkers to practically inform clinical trial design and decision-making concerning immune checkpoint inhibitor-based treatment strategies in NSCLC
  • Apply practical strategies across multidisciplinary teams to proactively counsel patients, and identify and mitigate the impact on management of treatment-related toxicities associated with immune checkpoint inhibition therapy

Faculty, Staff, and Planners' Disclosure


Benjamin P. Levy
Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: Eisai, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb


Charu Aggarwal
Charu Aggarwal, MD, MPH
Assistant Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Consultant: Bristol-Myers Squibb, Celgene, MedImmune

Stephen Liu
Stephen Liu, MD
Assistant Professor
Georgetown University Medical Center
Washington, DC

Disclosures: Grant/Research Support: AstraZeneca, Bayer, Clovis Oncology, Corvus Pharmaceuticals, Esanex, Genentech, Lycera, Medlmmune, Merck & Co, Inc., Molecular Partners, OncoMed Pharmaceuticals, Pfizer, Threshold Pharmaceuticals; Consultant: AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Heron Therapeutics, Pfizer, Regeneron, Taiho Oncology, Takeda Pharmaceutical Company

Hossein Borghaei
Hossein Borghaei, MS, DO
Chief, Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant/Research Support: Millennium, Merck/Celgene, Bristol-Myers Squibb/Lilly; Consultant: Bristol-Myers Squibb, Lilly, Genentech, Celgene, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, AbbVie

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By